Gilead Science has announced that together with Kite, a Gilead company, it will present over 25 abstracts, including 6 oral presentations, at the 2026 ASCO Annual Meeting (May 29-June 2) and the 2026 EHA Congress (June 11-June 14). These presentations underscore the increasing diversity of Gilead’s oncology portfolio and pipeline reflecting a growing body of evidence across both solid tumors and hematologic malignancies. Collectively, the data demonstrate Gilead and Kite’s leadership in Antibody-Drug Conjugates (ADCs) and CAR T-cell therapy.

Key presentations support continued momentum ahead of near-term potential launch opportunities, including new data analyses for Trodelvy (sacituzumab govitecan-hziy) in first-line metastatic Triple-Negative Breast Cancer (mTNBC) and anitocabtagene autoleucel (anito-cel), an investigational agent for Relapsed or Refractory Multiple Myeloma (RRMM). Together with abstracts addressing earlier-stage innovation, manufacturing experience and real-world evidence, these data highlight a portfolio that is increasingly positioned to deliver durable impact at scale.

Dietmar Berger, MD, PhD, Chief Medical Officer (CMO), Gilead Sciences, said, “We are at a pivotal inflection point in the evolution of our oncology portfolio, with late-stage programs advancing alongside a rapidly maturing pipeline. The data we are presenting at ASCO and EHA highlight the trajectory we are building across Antibody-Drug Conjugates and cell therapy, while reinforcing the clinical, manufacturing and operational foundation to sustain long-term leadership in oncology and deliver meaningful advances for people living with cancer.”